A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of
Cabozantinib (XL184) in Subjects with Radioiodine-Refractory
Differentiated Thyroid Cancer Who Have Progressed after Prior
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other exclusion criteria may apply.